Addison Advisors LLC Grows Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Addison Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 863.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 14,608 shares of the company’s stock after purchasing an additional 13,091 shares during the period. Addison Advisors LLC’s holdings in Takeda Pharmaceutical were worth $208,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth about $108,000. Envestnet Portfolio Solutions Inc. raised its stake in shares of Takeda Pharmaceutical by 7.4% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock worth $358,000 after purchasing an additional 1,778 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Takeda Pharmaceutical by 5.4% during the first quarter. SG Americas Securities LLC now owns 16,099 shares of the company’s stock worth $224,000 after purchasing an additional 824 shares during the period. Atomi Financial Group Inc. grew its position in Takeda Pharmaceutical by 53.6% in the 1st quarter. Atomi Financial Group Inc. now owns 20,205 shares of the company’s stock valued at $281,000 after buying an additional 7,053 shares during the last quarter. Finally, Sei Investments Co. increased its stake in Takeda Pharmaceutical by 6.7% in the 1st quarter. Sei Investments Co. now owns 372,975 shares of the company’s stock valued at $5,181,000 after buying an additional 23,525 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Down 0.9 %

Shares of NYSE:TAK opened at $13.66 on Tuesday. The company has a market cap of $43.45 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 0.26 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The firm’s 50-day simple moving average is $14.38 and its 200-day simple moving average is $13.82. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.